CRISPR THERAPTC (NASDAQ:CRSP) CEO Rodger Novak sold 5,303 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $15.02, for a total transaction of $79,651.06. Following the completion of the transaction, the chief executive officer now owns 1,219,208 shares in the company, valued at approximately $18,312,504.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Rodger Novak also recently made the following trade(s):

  • On Tuesday, May 30th, Rodger Novak sold 3,650 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $15.02, for a total transaction of $54,823.00.
  • On Wednesday, May 17th, Rodger Novak sold 50,000 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.26, for a total transaction of $813,000.00.
  • On Friday, May 5th, Rodger Novak sold 616 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.92, for a total transaction of $10,422.72.
  • On Thursday, May 4th, Rodger Novak sold 49,384 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.30, for a total transaction of $804,959.20.
  • On Thursday, April 20th, Rodger Novak sold 50,000 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.88, for a total transaction of $894,000.00.

CRISPR THERAPTC (NASDAQ:CRSP) traded down 2.67% on Monday, hitting $14.21. 129,802 shares of the stock traded hands. The company’s market capitalization is $568.36 million. The firm has a 50-day moving average price of $15.90 and a 200-day moving average price of $18.80. CRISPR THERAPTC has a 12 month low of $11.63 and a 12 month high of $25.00.

CRISPR THERAPTC (NASDAQ:CRSP) last released its earnings results on Thursday, May 11th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.06. The company had revenue of $2.70 million during the quarter. Analysts forecast that CRISPR THERAPTC will post ($2.41) earnings per share for the current year.

Insider Buying and Selling by Quarter for CRISPR THERAPTC (NASDAQ:CRSP)

ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/12/rodger-novak-sells-5303-shares-of-crispr-theraptc-crsp-stock.html.

Several brokerages have recently issued reports on CRSP. Chardan Capital began coverage on shares of CRISPR THERAPTC in a research note on Monday, March 27th. They issued a “buy” rating and a $23.50 target price on the stock. Piper Jaffray Companies set a $21.00 target price on shares of CRISPR THERAPTC and gave the stock a “buy” rating in a research note on Thursday, February 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. CRISPR THERAPTC currently has an average rating of “Buy” and a consensus target price of $23.10.

A number of hedge funds have recently added to or reduced their stakes in the company. Clough Capital Partners L P bought a new stake in CRISPR THERAPTC during the fourth quarter worth approximately $16,676,000. Wellington Management Group LLP boosted its stake in CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the period. Franklin Resources Inc. bought a new stake in CRISPR THERAPTC during the fourth quarter worth approximately $14,389,000. New Leaf Venture Partners L.L.C. bought a new stake in CRISPR THERAPTC during the fourth quarter worth approximately $11,882,000. Finally, Orbimed Advisors LLC bought a new stake in CRISPR THERAPTC during the fourth quarter worth approximately $7,541,000. Institutional investors own 24.08% of the company’s stock.

About CRISPR THERAPTC

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.